Validation of HPLC analysis method of a novel antihypertensive agent MS23 in rat plasma

Ting Wang, Laura M. Fox, Desuo Wang

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

MS23 is a vasodilator with unique dual action pharmacological profile to inhibit type 4 PDE and antagonize L-type calcium channels. We validated an analytical protocol for MS23 in rat plasma using high performance liquid chromatography (HPLC). A C18 column and a phosphate/acetonitrite buffer were used for chromatographic separation. UV detection was performed at 307 nm. The calibration curve for MS23 was linear in the range from 50 to 10,000 ng/ml. The limit of quantification (LOQ) was 50 ng/ml. The results demonstrate that the method has linearity (R = 0.9989), specificity, and acceptable precision/accuracy. This method is simple, economic, and sufficient for in vivo pharmacokinetic studies on the compound.

Original languageEnglish (US)
Pages (from-to)13-17
Number of pages5
JournalJournal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
Volume830
Issue number1
DOIs
StatePublished - Jan 2 2006
Externally publishedYes

Fingerprint

L-Type Calcium Channels
Pharmacokinetics
High performance liquid chromatography
Vasodilator Agents
Antihypertensive Agents
Rats
Buffers
Phosphates
High Pressure Liquid Chromatography
Calibration
Plasmas
Economics
Pharmacology

Keywords

  • Antihypertensive
  • Calcium channel antagonist
  • Dual action
  • MS23
  • PDE4 inhibitor
  • Validation

ASJC Scopus subject areas

  • Biochemistry

Cite this

Validation of HPLC analysis method of a novel antihypertensive agent MS23 in rat plasma. / Wang, Ting; Fox, Laura M.; Wang, Desuo.

In: Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, Vol. 830, No. 1, 02.01.2006, p. 13-17.

Research output: Contribution to journalArticle

@article{254954494cdd4bb1876fc6121c3a19a8,
title = "Validation of HPLC analysis method of a novel antihypertensive agent MS23 in rat plasma",
abstract = "MS23 is a vasodilator with unique dual action pharmacological profile to inhibit type 4 PDE and antagonize L-type calcium channels. We validated an analytical protocol for MS23 in rat plasma using high performance liquid chromatography (HPLC). A C18 column and a phosphate/acetonitrite buffer were used for chromatographic separation. UV detection was performed at 307 nm. The calibration curve for MS23 was linear in the range from 50 to 10,000 ng/ml. The limit of quantification (LOQ) was 50 ng/ml. The results demonstrate that the method has linearity (R = 0.9989), specificity, and acceptable precision/accuracy. This method is simple, economic, and sufficient for in vivo pharmacokinetic studies on the compound.",
keywords = "Antihypertensive, Calcium channel antagonist, Dual action, MS23, PDE4 inhibitor, Validation",
author = "Ting Wang and Fox, {Laura M.} and Desuo Wang",
year = "2006",
month = "1",
day = "2",
doi = "10.1016/j.jchromb.2005.10.009",
language = "English (US)",
volume = "830",
pages = "13--17",
journal = "Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences",
issn = "1570-0232",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Validation of HPLC analysis method of a novel antihypertensive agent MS23 in rat plasma

AU - Wang, Ting

AU - Fox, Laura M.

AU - Wang, Desuo

PY - 2006/1/2

Y1 - 2006/1/2

N2 - MS23 is a vasodilator with unique dual action pharmacological profile to inhibit type 4 PDE and antagonize L-type calcium channels. We validated an analytical protocol for MS23 in rat plasma using high performance liquid chromatography (HPLC). A C18 column and a phosphate/acetonitrite buffer were used for chromatographic separation. UV detection was performed at 307 nm. The calibration curve for MS23 was linear in the range from 50 to 10,000 ng/ml. The limit of quantification (LOQ) was 50 ng/ml. The results demonstrate that the method has linearity (R = 0.9989), specificity, and acceptable precision/accuracy. This method is simple, economic, and sufficient for in vivo pharmacokinetic studies on the compound.

AB - MS23 is a vasodilator with unique dual action pharmacological profile to inhibit type 4 PDE and antagonize L-type calcium channels. We validated an analytical protocol for MS23 in rat plasma using high performance liquid chromatography (HPLC). A C18 column and a phosphate/acetonitrite buffer were used for chromatographic separation. UV detection was performed at 307 nm. The calibration curve for MS23 was linear in the range from 50 to 10,000 ng/ml. The limit of quantification (LOQ) was 50 ng/ml. The results demonstrate that the method has linearity (R = 0.9989), specificity, and acceptable precision/accuracy. This method is simple, economic, and sufficient for in vivo pharmacokinetic studies on the compound.

KW - Antihypertensive

KW - Calcium channel antagonist

KW - Dual action

KW - MS23

KW - PDE4 inhibitor

KW - Validation

UR - http://www.scopus.com/inward/record.url?scp=29244470474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29244470474&partnerID=8YFLogxK

U2 - 10.1016/j.jchromb.2005.10.009

DO - 10.1016/j.jchromb.2005.10.009

M3 - Article

VL - 830

SP - 13

EP - 17

JO - Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

JF - Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

SN - 1570-0232

IS - 1

ER -